100 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–867. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the AFFIRM study. Circulation 2004; 109: 1509–1513. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007; 50: 2156–2161. Albers GW, Dalen JE, Laupacis A, et al. Antithrmbotic therapy in atrial fibrillation. Chest 2001; ll9(Suppl 1): 194S. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med 1996; 335: 540–546. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685–2692. Pisters R, Lane DA, Nieuwelaat R, et al. A novel user- friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest 2010; 138: 1093–1100. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anti- coagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58: 395–401. Armaganijan L, Eikelboom J, Healey JS, et al. New pharma- cotherapy for stroke prevention in atrial fibrillation. Adv Ther 2009; 26: 1058–1071. Wann S, Curtis AB, Ellenbogen KA, et al, Recommendation for emerging antithrombotic agents 2011 focused update recommendation comments. J Am Coll Cardiol 2011; 57; 1330–1337. Marcucci M, Iorio A, Nobili A, et al. Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Inten Med 2010; 21: 516–523. Saxonhouse SJ, Curtis AB. Risks and benefits of rate control versus maintenance of sinus rhythm. Am J Cardiol 2003; 91: 27D–32D. Denus S, Sanoski CA, Carlsson J, et al. Rate vs rhythm control in patients with atrial fibrillation: A meta-analysis. Arch Intern Med 2005; 165: 258–262. Wyse DG, Waldo AL, Dimarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Eng J Med 2002; 347: 1825–1833. The AFFIRM investigators. Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow- 57 58 59 60 61 62 63 64 65 66 67 68 69 70 Franken RA et al. Atrial fibrillation in the elderly up investigation of rhythm management (AFFIRM) study. Circulation 2004; 109: 1509–1513. Zimerman LI, Fenelon G, Martinelli Filho M, et al. Sociedade brasileira de cardiologia. diretrizes brasileiras de fibrilação atrial. Arq Bras Cardiol 2009; 92(6 Supl.1): S1–S39. Duray GZ, Ehrlich JR, Hohnloser SH. Dronedarone: A novel antiarrhythmic agent for the treatment of atrial fibrillation. Curr Opin Cardiol 2010, 25: 53–58. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357: 987–999. Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur Heart J 2003; 24: 1481–1487. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Eng J Med 2009; 360: 668–678. Wood S. Dronedarone trial suspended due to CV events in permanent atrial fibrillation Sanofi provides Multaq phase III B PALLAS trial uptodate (press release). http://www.theheart.org/ article/1251405.do (accessed on July 7, 201) Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology Guidelines. Part I: Primary prevention. Europace 2011; 13: 308–328. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/ HRS Focused Update incorporated into the ACC/AHA/ESC 2006 Guidelines for Management of Patients With Atrial Fib- rillation (Updating the 2006 Guideline) A Report of the Ame- rican College of Cardiology Foundation/American Heart As- sociation Task Force on Practice Guidelines. Circulation 2011; 123: E269–E367. Camm JA, Kirchhof P, Lip GYH. et al. Guidelines for the management of atrial fibrillation the task force for the mana- gement of atrial fibrillation of the European Society of Car- diology (ESC). Europace 2010; 12: 1360–1420. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins. N Engl J Med 1998; 339: 659–666. Noheria A, Kumar A, Wylie JV Jr, et al. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med 2008; 168: 581–586. Pinter A, Dorian P. New Approaches to Atrial Fibrillation Management: Treat the Patient, not the ECG. Cardiovasc Ther 2010; 5: 302–310. Zimerman LI., Fenelon G, Filho MM, et al. Diretrizes brasileiras de fibrilação atrial. Arq Bras Cardiol 2009; 92(6 Supl 1): S1–S39. Gravina CF, Rosa RF, Franken RA, et al. Sociedade brasileira de cardiologia. II diretrizes brasileiras em cardiogeriatria. Arq Bras Cardiol 2010; 95(3 Supl. 2): S1–S112. Journal of Geriatric Cardiology | jgc@jgc301.com; http://www.jgc301.com